Defects in processing and trafficking of the cystic fibrosis transmembrane conductance regulator - PubMed (original) (raw)
Review
Defects in processing and trafficking of the cystic fibrosis transmembrane conductance regulator
W R Skach. Kidney Int. 2000 Mar.
Free article
Abstract
Cystic fibrosis (CF) is caused by inherited mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR), a cAMP-regulated chloride channel expressed in epithelial tissues. Most mutations in CF patients result in rapid intracellular degradation of the CFTR protein. While this defect is thought to result from abnormal protein folding, it is unclear how mutant and wild-type (WT) proteins differ in structure, how the cell is able to distinguish these differences, and how the fate of the mutant protein is determined. By examining the initial steps of CFTR assembly into the endoplasmic reticulum (ER) membrane, it has recently been shown that CFTR utilizes two redundant translocation pathways to direct N-terminus folding events. Mutations that block one pathway therefore do not alter transmembrane topology, but rather appear to disrupt intracellular trafficking through perturbations in higher order tertiary structure. These studies suggest that cellular quality control machinery acts at least in part, by monitoring proper interactions between CFTR subdomains. The end result of this process is the conversion of misfolded CFTR into a membrane-bound, polyubiquitinated complex. This complex recruits cytosolic degradation machinery to the endoplasmic reticulum membrane where CFTR is degraded as it is extracted from the lipid bilayer. Understanding how cellular machinery mediates this process will be an important step in designing strategies to modify protein folding and degradation in CF and related ion channelopathies.
Similar articles
- Degradation of CFTR by the ubiquitin-proteasome pathway.
Ward CL, Omura S, Kopito RR. Ward CL, et al. Cell. 1995 Oct 6;83(1):121-7. doi: 10.1016/0092-8674(95)90240-6. Cell. 1995. PMID: 7553863 - COOH-terminal truncations promote proteasome-dependent degradation of mature cystic fibrosis transmembrane conductance regulator from post-Golgi compartments.
Benharouga M, Haardt M, Kartner N, Lukacs GL. Benharouga M, et al. J Cell Biol. 2001 May 28;153(5):957-70. doi: 10.1083/jcb.153.5.957. J Cell Biol. 2001. PMID: 11381082 Free PMC article. - Control of cystic fibrosis transmembrane conductance regulator membrane trafficking: not just from the endoplasmic reticulum to the Golgi.
Farinha CM, Matos P, Amaral MD. Farinha CM, et al. FEBS J. 2013 Sep;280(18):4396-406. doi: 10.1111/febs.12392. Epub 2013 Jul 5. FEBS J. 2013. PMID: 23773658 Review. - Cystic fibrosis transmembrane conductance regulator (CFTR) and renal function.
Stanton BA. Stanton BA. Wien Klin Wochenschr. 1997 Jun 27;109(12-13):457-64. Wien Klin Wochenschr. 1997. PMID: 9261986 Review.
Cited by
- Elexacaftor Mediates the Rescue of F508del CFTR Functional Expression Interacting with MSD2.
Bongiorno R, Ludovico A, Moran O, Baroni D. Bongiorno R, et al. Int J Mol Sci. 2023 Aug 16;24(16):12838. doi: 10.3390/ijms241612838. Int J Mol Sci. 2023. PMID: 37629017 Free PMC article. - More Than Just Simple Interaction between STIM and Orai Proteins: CRAC Channel Function Enabled by a Network of Interactions with Regulatory Proteins.
Berlansky S, Humer C, Sallinger M, Frischauf I. Berlansky S, et al. Int J Mol Sci. 2021 Jan 5;22(1):471. doi: 10.3390/ijms22010471. Int J Mol Sci. 2021. PMID: 33466526 Free PMC article. Review. - Cystic Fibrosis: Overview of the Current Development Trends and Innovative Therapeutic Strategies.
Almughem FA, Aldossary AM, Tawfik EA, Alomary MN, Alharbi WS, Alshahrani MY, Alshehri AA. Almughem FA, et al. Pharmaceutics. 2020 Jul 2;12(7):616. doi: 10.3390/pharmaceutics12070616. Pharmaceutics. 2020. PMID: 32630625 Free PMC article. Review. - Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
Amico G, Brandas C, Moran O, Baroni D. Amico G, et al. Int J Mol Sci. 2019 Nov 1;20(21):5463. doi: 10.3390/ijms20215463. Int J Mol Sci. 2019. PMID: 31683989 Free PMC article. - Functional and structural analysis of rare SLC2A2 variants associated with Fanconi-Bickel syndrome and metabolic traits.
Enogieru OJ, Ung PMU, Yee SW, Schlessinger A, Giacomini KM. Enogieru OJ, et al. Hum Mutat. 2019 Jul;40(7):983-995. doi: 10.1002/humu.23758. Epub 2019 Apr 25. Hum Mutat. 2019. PMID: 30950137 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical